| General Information of Drug Metabolite (DM) (ID: DM019109) |
| DM Name |
AZD2624 Metabolite M1
|
| Structure |
|
|
3D MOL is unavailable
|
2D MOL is unavailable
|
|
|
|
|
|
|
|
| Full List of Drug-Metabolizing Enzyme (DME) Related to This DM |
| DME(s) Producing This DM through Metabolism |
| DME Name |
DME ID |
Reactant |
Reaction |
Related Drug |
REF |
|
Cytochrome P450 2C9 (CYP2C9)
|
DME0019
|
| Unclear - Unclear |
AZD2624
|
[1] |
|
Cytochrome P450 3A4 (CYP3A4)
|
DME0001
|
| Unclear - Unclear |
AZD2624
|
[1] |
|
Cytochrome P450 3A5 (CYP3A5)
|
DME0012
|
| Unclear - Unclear |
AZD2624
|
[1] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Full List of Drug(s) That Produce This DM By Metabolism |
| AZD2624 |
DR3199
|
Phase 2 |
Multiple sclerosis |
|
|
| References |
| 1 |
In vitro assessment of metabolic drugCdrug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P(450) enzyme identification, inhibition, and induction studies
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
